Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab + GDP in Relapsed/Refractory CD20+ Aggressive NHL
NCT02750670Phase 2Completed
- Sponsor
- University Health Network
- Start
- Mar 2017
- Primary completion
- Sep 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in non-Hodgkin lymphoma (NHL), sponsored by University Health Network. Started Mar 2017; status: completed.
02
Drugs
obinutuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02750670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750670.